Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.66 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | CHRND | Q07001 | 5/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.56 |
| ▸ | CHRNG | P07510 | 1/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651208 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL6651206 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL4581440 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL16466484 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL4580946 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL28124 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL8371127 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL3452191 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL13279358 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL3802383 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | claimed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | claimed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | claimed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | claimed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | claimed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | claimed |
| EP-4662197-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024165426-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-15 | — | — | WO | disclosed |
| EP-4414360-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-14 | — | — | EP | disclosed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-2288374-B1 | NOVEL N-AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF HUMAN GH-RH | THE UNIV OF MIAMI (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20150250882-A1 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | NOVO NORDISK HEALTHCARE AG (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2908845-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY | Novo Nordisk Health Care AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014177406-A1 | COMPOSITION COMPRISING AT LEAST THREE ACTIVE AGENTS FOR COLOURING AND/OR PIGMENTING KERATIN MATERIALS | L'OREAL (FR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014060512-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| EP-1888180-A2 | SELF-TANNING COMPOSITION HAVING A UV PROTECTIVE EFFECT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131247-A2 | SELF-TANNING COMPOSITION HAVING A UV PROTECTIVE EFFECT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | FAAH 858/4885ITGB3 4058/4885ITGA2B 3499/4885 |
| US-20150250882-A1 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | GHRHR, GHSR, GHITM | FAAH 53/4885ITGB3 4140/4885ITGA2B 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.